drugset / Trial / NCT05569434
68Ga-P16-093 PET/CT Imaging in Glioma Patients
NaSingle-groupOpen-labelDiagnostic
Summary
PSMA is highly expressed on the cell surface of the microvasculature of several solid tumors, including glioma. This makes it a potentially imaging target for the detection and grading of gliomas. This pilot study was designed to evaluate the diagnostic performance of 68Ga-P16-093, a novel radiopharmaceutical targeting PSMA, which was compared with MRI in the same group of glioma patients.
Timeline
- Start
- 2021-11-28
- Primary completion
- 2023-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-P16-093 | Diagnostic / imaging agent | 1.5 mbq/kg | Intravenous |
| Subject | 68Ga-P16-093 | Diagnostic / imaging agent | 1.8 mbq/kg | Intravenous |